Biotheranostics Announces Inclusion of Breast Cancer Index in the National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines for Prediction of Benefit from Extended Endocrine Therapy

Ordering A Test

How to Order a Test

Ordering a test from Biotheranostics is easy. Follow the simple steps from the links below.

The only robust, validated tool to help with clinical decision-making for extended endocrine treatment

  • Predictive for likelihood of benefit from extended endocrine therapy
  • Prognostic for risk of late distant recurrence (Years 5 – 10)

CancerTYPE ID helps guide your clinical decision-making through every phase of disease management

  • CancerTYPE ID is a most validated gene expression-based assay to help achieve an accurate diagnosis